These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18819516)

  • 1. Liposome-based intracellular kinetics of doxorubicin in K562/DOX cells.
    Xu DH; Gao JQ; Liang WQ
    Pharmazie; 2008 Sep; 63(9):646-9. PubMed ID: 18819516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
    Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
    J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.
    Eliaz RE; Szoka FC
    Cancer Res; 2001 Mar; 61(6):2592-601. PubMed ID: 11289136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
    Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
    Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
    Sebille S; Morjani H; Poullain MG; Manfait M
    Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
    Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
    Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
    Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
    Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells.
    Venne A; Li S; Mandeville R; Kabanov A; Alakhov V
    Cancer Res; 1996 Aug; 56(16):3626-9. PubMed ID: 8705995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin.
    Wang SN; Deng YH; Xu H; Wu HB; Qiu YK; Chen DW
    Eur J Pharm Biopharm; 2006 Jan; 62(1):32-8. PubMed ID: 16226883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.